TRCT
TVTX icon

Tower Research Capital (TRC)’s Travere Therapeutics TVTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Buy
9,847
+9,386
+2,036% +$281K 0.01% 1321
2025
Q4 		$17.6K Sell
461
-5,065
-92% -$165K ﹤0.01% 3199
2025
Q3 		$132K Sell
5,526
-19,472
-78% -$366K ﹤0.01% 1791
2025
Q2 		$370K Buy
24,998
+21,474
+609% +$356K 0.01% 1230
2025
Q1 		$63.2K Sell
3,524
-17,843
-84% -$362K ﹤0.01% 2056
2024
Q4 		$372K Buy
21,367
+14,501
+211% +$256K 0.01% 1264
2024
Q3 		$96.1K Sell
6,866
-6,951
-50% -$72.4K ﹤0.01% 2264
2024
Q2 		$114K Buy
13,817
+12,717
+1,156% +$85.6K ﹤0.01% 2491
2024
Q1 		$8.48K Sell
1,100
-4,933
-82% -$41.6K ﹤0.01% 4012
2023
Q4 		$54.2K Sell
6,033
-1,896
-24% -$13.8K ﹤0.01% 3078
2023
Q3 		$70.9K Buy
7,929
+1,876
+31% +$26.5K ﹤0.01% 2252
2023
Q2 		$93K Buy
6,053
+2,914
+93% +$53K ﹤0.01% 2076
2023
Q1 		$71K Sell
3,139
-2,197
-41% -$46.7K ﹤0.01% 2193
2022
Q4 		$112K Sell
5,336
-2,763
-34% -$58.6K ﹤0.01% 1746
2022
Q3 		$199K Sell
8,099
-11,762
-59% -$304K ﹤0.01% 1942
2022
Q2 		$481K Buy
19,861
+9,171
+86% +$231K 0.01% 1158
2022
Q1 		$275K Buy
10,690
+3,389
+46% +$90K ﹤0.01% 1516
2021
Q4 		$226K Buy
7,301
+1,822
+33% +$51.3K ﹤0.01% 1664
2021
Q3 		$133K Buy
5,479
+523
+11% +$9.61K ﹤0.01% 2159
2021
Q2 		$72K Buy
4,956
+2,606
+111% +$51.4K ﹤0.01% 2711
2021
Q1 		$59K Buy
2,350
+799
+52% +$22.1K ﹤0.01% 2984
2020
Q4 		$42K Sell
1,551
-539
-26% -$12.6K ﹤0.01% 3284
2020
Q3 		$39K Sell
2,090
-3,035
-59% -$59K ﹤0.01% 3643
2020
Q2 		$105K Buy
+5,125
New +$81.6K ﹤0.01% 2413
2019
Q4 		– Sell
-1,339
Closed -$16K – 4372
2019
Q3 		$16K Buy
1,339
+30
+2% +$496 ﹤0.01% 2635
2019
Q2 		$26K Buy
+1,309
New +$25.8K ﹤0.01% 2017
2018
Q1 		– Sell
-1,383
Closed -$29K – 3840
2017
Q4 		$29K Sell
1,383
-5,338
-79% -$122K ﹤0.01% 1766
2017
Q3 		$167K Buy
6,721
+6,421
+2,140% +$141K 0.01% 897
2017
Q2 		$6K Buy
+300
New +$5.44K ﹤0.01% 1916
2017
Q1 		– Sell
-1,426
Closed -$27K – 3926
2016
Q4 		$27K Buy
1,426
+487
+52% +$9.96K ﹤0.01% 1891
2016
Q3 		$21K Buy
+939
New +$17.9K ﹤0.01% 1590
2016
Q1 		– Sell
-531
Closed -$10K – 4942
2015
Q4 		$10K Sell
531
-669
-56% -$13.4K ﹤0.01% 2148
2015
Q3 		$24K Sell
1,200
-529
-31% -$15.7K ﹤0.01% 1587
2015
Q2 		$58K Sell
1,729
-3,814
-69% -$104K 0.01% 1250
2015
Q1 		$133K Buy
5,543
+3,296
+147% +$50.3K 0.02% 671
2014
Q4 		$28K Sell
2,247
-3,560
-61% -$36.8K ﹤0.01% 1381
2014
Q3 		$52K Buy
+5,807
New +$68.3K 0.01% 1503
2014
Q2 		– Sell
-5,186
Closed -$110K – 4651
2014
Q1 		$110K Buy
+5,186
New +$79.7K 0.01% 654

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tower Research Capital (TRC)'s TVTX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Travere Therapeutics (TVTX) stake by 2,036% in Q1 2026, buying an estimated $281K and bringing the position to 9,847 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #1321.

Tower Research Capital (TRC) first reported a position in TVTX in Q1 2014 and has held it in 38 quarters since. The position peaked at $481K in Q2 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Tower Research Capital (TRC) held 9,847 shares of Travere Therapeutics worth $293K as of Q1 2026.
  • Tower Research Capital (TRC) bought 9,386 Travere Therapeutics shares in Q1 2026, an estimated $281K.
  • Travere Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1321 holding.
  • Tower Research Capital (TRC) first reported a position in Travere Therapeutics in Q1 2014 and has held it in 38 quarters since.
  • Tower Research Capital (TRC)'s Travere Therapeutics position peaked at $481K in Q2 2022.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.